Latest filings (excl ownership)
25-NSE
Exchange delisting
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Feb 24
8-K
Bankruptcy or Receivership
2 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
23 Jan 24
8-K
MedAvail Receives Nasdaq Notification of Non-Compliance Related
17 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Other Events
14 Nov 23
8-K
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
18 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
MedAvail Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K
MedAvail Announces 1-for-50 Reverse Stock Split
31 Jul 23
EFFECT
Notice of effectiveness
20 Jul 23
CORRESP
Correspondence with SEC
18 Jul 23
S-3/A
Shelf registration (amended)
14 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
S-8
Registration of securities for employees
29 Jun 23
S-3
Shelf registration
29 Jun 23
8-K
Other Events
29 Jun 23
8-K
Changes in Registrant's Certifying Accountant
16 Jun 23
DEFA14A
Additional proxy soliciting materials
19 May 23
10-Q
2023 Q1
Quarterly report
18 May 23
8-K
MedAvail Reports First Quarter 2023 Financial Results
18 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Changes in Registrant's Certifying Accountant
8 May 23
8-K
Other Events
4 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Cost Associated with Exit or Disposal Activities
28 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
8-K
Departure of Directors or Certain Officers
17 Apr 23
10-K
2022 FY
Annual report
14 Apr 23
8-K
MedAvail Reports Fourth Quarter and Full-Year 2022 Financial Results
13 Apr 23
8-K/A
Completion of Acquisition or Disposition of Assets
6 Apr 23
8-K
Entry into a Material Definitive Agreement
3 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
MedAvail Announces Closing of $16 Million Private Placement
14 Mar 23
8-K
Entry into a Material Definitive Agreement
16 Feb 23
8-K
Departure of Directors or Certain Officers
10 Feb 23
8-K
MedAvail announces Sale of Pharmacy Assets to CVS Pharmacy
26 Jan 23
8-K
MedAvail announces Strategic Restructuring of Business to Focus on Profitability
19 Jan 23
Latest ownership filings
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 24
4
Robert C. Faulkner
6 Feb 24
SC 13D/A
Redmile Group, LLC
6 Feb 24
4
Ramona Seabaugh
2 Oct 23
4
Mark Edward Doerr
21 Aug 23
4
Ramona Seabaugh
21 Aug 23
4
Jeremy Green
21 Jun 23
SC 13D/A
Redmile Group, LLC
21 Jun 23
SC 13D/A
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
21 Jun 23
4
Fan Yu
21 Jun 23
4
Michael R Kramer
20 Jun 23
4
LAURIE MCGRAW
20 Jun 23
4
Glen D. Stettin
20 Jun 23
4
Paul D Johnson
20 Jun 23
4
Ramona Seabaugh
23 Mar 23
SC 13D/A
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
15 Mar 23
4
Fan Yu
15 Mar 23
SC 13D/A
Redmile Group, LLC
15 Mar 23
4
Jeremy Green
13 Mar 23
4
Ramona Seabaugh
7 Mar 23
4
Mark Edward Doerr
7 Mar 23
4
Ramona Seabaugh
3 Mar 23
4
Mark Edward Doerr
3 Mar 23
SC 13G
Alyeska Investment Group, L.P.
14 Feb 23
4
Jeremy Green
6 Jul 22
SC 13D/A
Redmile Group, LLC
6 Jul 22
4
Michael R Kramer
16 Jun 22
4
Glen D. Stettin
16 Jun 22
4
Gerald Gradwell
16 Jun 22
4
Paul D Johnson
16 Jun 22
4
LAURIE MCGRAW
16 Jun 22
3
ANAND PAREKH
23 May 22
4
Steven Hess
12 Apr 22
3
Initial statement of insider ownership
6 Apr 22
4
Jeremy Green
6 Apr 22
SC 13D/A
Redmile Group, LLC
6 Apr 22
SC 13D/A
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
6 Apr 22
4
Fan Yu
6 Apr 22
4
LAURIE MCGRAW
18 Mar 22
4
Paul D Johnson
18 Mar 22